These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 11498597

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
    Stacy M, Silver D.
    Parkinsonism Relat Disord; 2008; 14(2):85-92. PubMed ID: 18083605
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease.
    Rinne JO, Laihinen A, Någren K, Bergman J, Solin O, Haaparanta M, Ruotsalainen U, Rinne UK.
    J Neurosci Res; 1990 Dec; 27(4):494-9. PubMed ID: 1981915
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Relief of akinesia by apomorphine and cerebral metabolic changes in Parkinson's disease.
    Broussolle E, Cinotti L, Pollak P, Landais P, Le Bars D, Galy G, Lavenne F, Khalfallah Y, Chazot G, Mauguière F.
    Mov Disord; 1993 Oct; 8(4):459-62. PubMed ID: 8232355
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Future delivery systems for apomorphine in patients with Parkinson's disease.
    van Laar T, Van der Geest R, Danhof M.
    Adv Neurol; 1999 Oct; 80():535-44. PubMed ID: 10410768
    [No Abstract] [Full Text] [Related]

  • 30. Apomorphine-induced penile erections in Parkinson's disease.
    O'Sullivan JD, Hughes AJ.
    Mov Disord; 1998 May; 13(3):536-9. PubMed ID: 9613749
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Placebo effect in Parkinson's disease].
    Miwa H.
    Brain Nerve; 2007 Feb; 59(2):139-46. PubMed ID: 17380778
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
    Rambour M, Moreau C, Salleron J, Devos D, Kreisler A, Mutez E, Simonin C, Annic A, Dujardin K, Destée A, Defebvre L.
    Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Parkinson's disease and its chemotherapy.
    Hornykiewicz O.
    Biochem Pharmacol; 1975 May 15; 24(10):1061-5. PubMed ID: 239718
    [No Abstract] [Full Text] [Related]

  • 38. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for beta-CFT binding with positron emission tomography.
    Ouchi Y, Yoshikawa E, Okada H, Futatsubashi M, Sekine Y, Iyo M, Sakamoto M.
    Ann Neurol; 1999 May 15; 45(5):601-10. PubMed ID: 10319882
    [Abstract] [Full Text] [Related]

  • 39. Signal transduction pathway activity compensates dopamine D₂/D₃ receptor density changes in Parkinson's disease: a preliminary comparative human brain receptor autoradiography study with [³H]raclopride and [³⁵S]GTPγS.
    Farkas S, Nagy K, Jia Z, Hortobágyi T, Varrone A, Halldin C, Csiba L, Gulyás B.
    Brain Res; 2012 May 09; 1453():56-63. PubMed ID: 22480734
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.